MELBOURNE, AUSTRALIA / CRWEPRESSRELEASE / August 13, 2015 / Propanc Health Group Corporation (OTCMKTS:PPCH) (“Propanc” or “the Company”), an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from pancreatic and colorectal cancers, today announced that the Company has identified potential patent opportunities as a result of the ongoing research and development activities underway with its research partners.
As part of the R&D process, the Company regularly refers data generated to its patent attorneys for evaluation. Once the patent attorneys complete their analysis and provide their opinion, the Company will determine if it proceeds with filing a provisional patent application, which it plans to file in the United States as its preferred, priority jurisdiction.
“We are pleased to be making these important scientific discoveries in the cancer field and remain committed to growing the Company’s intellectual property oncology portfolio, which continues to build value for the Company and its shareholders, as we progress further down the pathway to commercialization,” said Dr. Julian Kenyon, Propanc’s Chief Scientific Officer. “Such activities are important when we move to license our products with potential suitors. A strong portfolio demonstrates the Company has an in depth knowledge of its technology and management of the R&D process, in addition to protecting the Company’s commercial interests.”
Presently, the Company has completed its round of recent pilot animal studies and preparation for the next round of full scale efficacy studies are underway, which will be used to support planned regulatory meetings, as well as future discussions with potential licensing partners. Additionally, the data generated could also supplement the Company’s provisional patent applications if the Company proceeds with filing.
“We wish to assure shareholders we are making good progress and continue to increase our investment into our R&D programs in order to complete pivotal studies to support an application for future human trials,” said James Nathanielsz, Propanc’s Chief Executive Officer. “Growing our intellectual property portfolio, advancing the development of our lead product candidate, and liaising with key stakeholders such as regulatory agencies to negotiate a pathway to commercialization will ensure we are proactive in achieving our long term vision.”
In order to continue to invest in R&D and progress the Company’s products into human trials, the Company is working closely with its Investment Banking Advisors, Maxim Group, and management believes it is close to identifying an avenue of finance which could meet these important objectives.
Further, the Company wishes to emphasize it remains committed to disclosing results from studies once they become available and evaluated fully by scientific experts. Conclusions made will be disclosed accurately and appropriately for shareholders in a timely manner.
Propanc is currently focused on developing new cancer treatments for patients suffering from pancreatic and colorectal cancers. Propanc have developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Propanc’s products involve or employ proenzymes, which are inactive precursors of enzymes.
In the near term, Propanc intend to target patients with limited remaining therapeutic options for the treatment of solid tumors such as colorectal or pancreatic tumors. In future, Propanc intend to development their lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening. For more information, visit: www.propanc.com.
Certain of the matters discussed in this announcement involve risks and uncertainties including, without limitation, those regarding the Company’s ability to establish and maintain the proprietary nature of its technology through the patent process, its ability to license from others patents and patent applications, if necessary, to develop certain products, its ability to implement its long range business plan for various applications of its technology, and its ability to enter into agreements with any necessary marketing and/or distribution partners for purposes of commercialization. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the company’s financial position. See Propanc’s most recent Quarterly Report on Form 10-Q and related 8K filings.
SOURCE: Propanc Health Group Corporation